Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
Basel, 26 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approva
Roche commences tender offer for all shares of GenMark Diagnostics, Inc. for $24.05 per share in cash
12:40pm, Thursday, 25'th Mar 2021
Basel, 25 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of GenMark Diagnostics, Inc. (NA
Roche (RHHBY) Stops Dosing in Huntington's Disease Study
10:36am, Tuesday, 23'rd Mar 2021
Roche (RHHBY) halts dosing in the phase III GENERATION HD1 study evaluating tominersen in manifest Huntington's disease following recommendation from an iDMC.
Ionis (IONS) Crashes as Roche-Partnered Huntington's Drug Fails
09:05am, Tuesday, 23'rd Mar 2021
Ionis (IONS) stock sinks as partner Roche stops dosing in a late-stage study on tominersen in Huntington's disease.
Roche launches new high throughput configurations for cobas pro integrated solutions to increase testing efficiency
02:03am, Tuesday, 23'rd Mar 2021
Basel, 23 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of eight new configurations for cobas pro integrated solutions, in countries accepting the CE mark. As a result,
Basel, 23 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today confirmed positive topline results from the largest trial to date assessing a COVID-19 treatment in infected non-hospitalised patients (
Roche provides update on tominersen programme in manifest Huntington's disease
04:00pm, Monday, 22'nd Mar 2021
Basel, 22 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the decision to discontinue dosing in the Phase III GENERATION HD1 study of tominersen in manifest Huntington's disease (HD).
Roche's (RHHBY) Tecentriq Meets Primary Goal in Lung Cancer Study
02:22pm, Monday, 22'nd Mar 2021
Roche's (RHHBY) Tecentriq meets primary endpoint of disease-free survival at the interim analysis in lung cancer patients.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizu
Investing In Roche Requires Patience For Pipeline To Unfold
03:17pm, Friday, 19'th Mar 2021
I'm long Roche but expect limited stock price appreciation potential for 2021.
Roche launches cobas pure integrated solutions analyser to help simplify operations in small to medium sized labs
02:00am, Wednesday, 17'th Mar 2021
Basel, 17 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of cobas pure integrated solutions in countries accepting the CE mark.3 This new compact analyser combines three
3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy
11:41am, Tuesday, 16'th Mar 2021
Roche Holding AG (OTC: RHHBY) acquired GenMark Diagnostics, Inc (NASDAQ: GNMK) in a $1.8 billion deal on Monday, the same day Veracyte Inc (NASDAQ: VCYT) announced it completed the acquisition o
Roche Annual General Meeting 2021
07:40am, Tuesday, 16'th Mar 2021
Basel, 16 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its shareholders approved all proposals of the Board of Directors at its ordinary Annual General Meeting (AGM). Owing to
Roche launches SARS-CoV-2 variant test to help monitor emerging coronavirus mutations
02:03am, Tuesday, 16'th Mar 2021
Basel, 16 March 2021- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of the cobas® SARS-CoV-2 Variant Set 1 Test to detect and differentiate mutations found in variants that originated
Basel, 16 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new exploratory 2-year longer-term data from Part 2 of SUNFISH, a global placebo-controlled study evaluating Evrysdi™ (risdi
